Atara Biotherape Financials
This page shows Atara Biotherape (ATRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Atara Biotherape has an operating margin of 29.7%, meaning the company retains $30 of operating profit per $100 of revenue. This strong profitability earns a score of 88/100, reflecting efficient cost management and pricing power. This is up from -64.7% the prior year.
Atara Biotherape's revenue declined 6.3% year-over-year, from $128.9M to $120.8M. This contraction results in a growth score of 23/100.
Atara Biotherape's current ratio of 0.82 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 11/100, which could limit financial flexibility.
While Atara Biotherape generated -$50.9M in operating cash flow, capex of $0 consumed most of it, leaving -$50.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Atara Biotherape scores -127.81, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($40.8M) relative to total liabilities ($58.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Atara Biotherape passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Atara Biotherape generates $-1.56 in operating cash flow (-$50.9M OCF vs $32.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Atara Biotherape earns $9.5 in operating income for every $1 of interest expense ($35.9M vs $3.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Atara Biotherape generated $120.8M in revenue in fiscal year 2025. This represents a decrease of 6.3% from the prior year.
Atara Biotherape's EBITDA was $38.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 148.4% from the prior year.
Atara Biotherape reported $32.7M in net income in fiscal year 2025. This represents an increase of 138.3% from the prior year.
Atara Biotherape earned $2.57 per diluted share (EPS) in fiscal year 2025. This represents an increase of 122.5% from the prior year.
Cash & Balance Sheet
Atara Biotherape generated -$50.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 26.1% from the prior year.
Atara Biotherape held $8.5M in cash against $0 in long-term debt as of fiscal year 2025.
Atara Biotherape had 7M shares outstanding in fiscal year 2025. This represents an increase of 25.0% from the prior year.
Margins & Returns
Atara Biotherape's operating margin was 29.7% in fiscal year 2025, reflecting core business profitability. This is up 94.4 percentage points from the prior year.
Atara Biotherape's net profit margin was 27.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 93.3 percentage points from the prior year.
Capital Allocation
Atara Biotherape invested $37.4M in research and development in fiscal year 2025. This represents a decrease of 75.3% from the prior year.
Atara Biotherape invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
ATRA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M-53.8% | $3.5M-80.4% | $17.6M-82.1% | $98.1M+199.7% | $32.8M-18.5% | $40.2M+40.3% | $28.6M+4.7% | $27.4M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | -$223K-107.6% | $2.9M-60.0% | $7.3M-73.4% | $27.4M-4.5% | $28.7M-34.6% | $43.9M+31.8% | $33.3M-26.8% | $45.5M |
| SG&A Expenses | $4.3M+7.3% | $4.0M-38.8% | $6.5M-43.2% | $11.5M+21.6% | $9.4M-9.4% | $10.4M+16.9% | $8.9M-19.8% | $11.1M |
| Operating Income | -$2.6M+28.3% | -$3.6M-211.8% | $3.2M-91.8% | $38.8M+418.0% | -$12.2M+43.9% | -$21.8M-19.3% | -$18.2M+41.7% | -$31.2M |
| Interest Expense | $894K-1.7% | $909K-6.5% | $972K-4.4% | $1.0M0.0% | $1.0M-14.0% | $1.2M-6.3% | $1.3M+9.5% | $1.2M |
| Income Tax | $0-100.0% | $28K+833.3% | $3K | $0+100.0% | -$19K-11.8% | -$17K | $0-100.0% | $24K |
| Net Income | -$3.4M+20.8% | -$4.3M-280.3% | $2.4M-93.7% | $38.0M+399.5% | -$12.7M+42.1% | -$21.9M-15.0% | -$19.0M+40.0% | -$31.8M |
| EPS (Diluted) | N/A | $-0.32-268.4% | $0.19-94.6% | $3.50 | N/A | $-2.93+5.5% | $-3.10 | $-5.65 |
ATRA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $20.2M-32.9% | $30.2M-18.3% | $36.9M-40.5% | $62.0M-43.1% | $109.1M-23.6% | $142.7M+21.7% | $117.3M-29.0% | $165.3M |
| Current Assets | $12.2M-33.7% | $18.4M-25.6% | $24.8M-8.9% | $27.2M-58.1% | $64.9M-29.4% | $91.9M+47.2% | $62.4M-41.4% | $106.4M |
| Cash & Equivalents | $8.5M+47.7% | $5.7M-66.0% | $16.9M+22.1% | $13.8M-44.7% | $25.0M-46.1% | $46.5M+48.3% | $31.3M-10.8% | $35.1M |
| Inventory | $0 | $0 | $0 | $0-100.0% | $10.7M-23.8% | $14.0M-25.4% | $18.7M+16.6% | $16.1M |
| Accounts Receivable | $1.3M-34.5% | $1.9M | $0-100.0% | $8.9M+498.9% | $1.5M+11.0% | $1.3M-44.9% | $2.4M-93.2% | $35.8M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $58.7M-12.1% | $66.8M-7.1% | $71.9M-38.6% | $117.1M-43.3% | $206.4M-11.5% | $233.2M+2.2% | $228.2M-13.4% | $263.6M |
| Current Liabilities | $14.9M-17.4% | $18.1M+24.0% | $14.6M-69.6% | $47.9M-64.4% | $134.6M-13.7% | $156.0M+5.2% | $148.3M-17.9% | $180.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$38.5M-5.1% | -$36.6M-4.5% | -$35.0M+36.4% | -$55.1M+43.4% | -$97.3M-7.4% | -$90.5M+18.3% | -$110.9M-12.8% | -$98.3M |
| Retained Earnings | -$2.0B-0.2% | -$2.0B-0.2% | -$2.0B+0.1% | -$2.0B+1.9% | -$2.1B-0.6% | -$2.0B-1.1% | -$2.0B-1.0% | -$2.0B |
ATRA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.7M+41.8% | -$9.8M-33.7% | -$7.3M+74.0% | -$28.1M-15.0% | -$24.5M-513.5% | -$4.0M+62.5% | -$10.6M+64.1% | -$29.6M |
| Capital Expenditures | $0 | $0 | $0 | $0-100.0% | $90K | $0-100.0% | $29K-77.2% | $127K |
| Free Cash Flow | -$5.7M+41.8% | -$9.8M-33.7% | -$7.3M+74.0% | -$28.1M-14.6% | -$24.6M-515.7% | -$4.0M+62.6% | -$10.7M+64.1% | -$29.7M |
| Investing Cash Flow | $8.4M+448.6% | -$2.4M+52.2% | -$5.1M-129.5% | $17.2M+409.4% | $3.4M+120.3% | -$16.7M-331.6% | $7.2M-51.1% | $14.7M |
| Financing Cash Flow | -$3K-100.3% | $1.0M-93.2% | $15.3M+6221.6% | -$250K+23.8% | -$328K-100.9% | $35.8M+11147.2% | -$324K-101.3% | $24.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ATRA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -160.7%-57.2pp | -103.5%-121.7pp | 18.2%-21.3pp | 39.5%+76.8pp | -37.3%+16.9pp | -54.1%+9.5pp | -63.7%+50.6pp | -114.2% |
| Net Margin | -213.5%-88.9pp | -124.6%-138.2pp | 13.6%-25.1pp | 38.7%+77.5pp | -38.8%+15.8pp | -54.5%+12.0pp | -66.5%+49.6pp | -116.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -16.8%-2.6pp | -14.3%-20.7pp | 6.5%-54.8pp | 61.3%+72.9pp | -11.6%+3.7pp | -15.3%+0.9pp | -16.2%+3.0pp | -19.2% |
| Current Ratio | 0.82-0.2 | 1.02-0.7 | 1.70+1.1 | 0.57+0.1 | 0.48-0.1 | 0.59+0.2 | 0.42-0.2 | 0.59 |
| Debt-to-Equity | -1.53+0.3 | -1.82+0.2 | -2.05+0.1 | -2.130.0 | -2.12+0.5 | -2.58-0.5 | -2.06+0.6 | -2.68 |
| FCF Margin | -357.2%-73.8pp | -283.4%-241.8pp | -41.6%-13.0pp | -28.7%+46.3pp | -75.0%-65.1pp | -9.9%+27.3pp | -37.3%+71.4pp | -108.7% |
Note: Shareholder equity is negative (-$38.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.82), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Atara Biotherape's annual revenue?
Atara Biotherape (ATRA) reported $120.8M in total revenue for fiscal year 2025. This represents a -6.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Atara Biotherape's revenue growing?
Atara Biotherape (ATRA) revenue declined by 6.3% year-over-year, from $128.9M to $120.8M in fiscal year 2025.
Is Atara Biotherape profitable?
Yes, Atara Biotherape (ATRA) reported a net income of $32.7M in fiscal year 2025, with a net profit margin of 27.1%.
What is Atara Biotherape's EBITDA?
Atara Biotherape (ATRA) had EBITDA of $38.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Atara Biotherape's operating margin?
Atara Biotherape (ATRA) had an operating margin of 29.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Atara Biotherape's net profit margin?
Atara Biotherape (ATRA) had a net profit margin of 27.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Atara Biotherape's free cash flow?
Atara Biotherape (ATRA) generated -$50.9M in free cash flow during fiscal year 2025. This represents a 26.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Atara Biotherape's operating cash flow?
Atara Biotherape (ATRA) generated -$50.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Atara Biotherape's total assets?
Atara Biotherape (ATRA) had $20.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Atara Biotherape's capital expenditures?
Atara Biotherape (ATRA) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Atara Biotherape spend on research and development?
Atara Biotherape (ATRA) invested $37.4M in research and development during fiscal year 2025.
What is Atara Biotherape's current ratio?
Atara Biotherape (ATRA) had a current ratio of 0.82 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Atara Biotherape's debt-to-equity ratio?
Atara Biotherape (ATRA) had a debt-to-equity ratio of -1.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Atara Biotherape's return on assets (ROA)?
Atara Biotherape (ATRA) had a return on assets of 161.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Atara Biotherape's cash runway?
Based on fiscal year 2025 data, Atara Biotherape (ATRA) had $8.5M in cash against an annual operating cash burn of $50.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Atara Biotherape's debt-to-equity ratio negative or unusual?
Atara Biotherape (ATRA) has negative shareholder equity of -$38.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Atara Biotherape's Altman Z-Score?
Atara Biotherape (ATRA) has an Altman Z-Score of -127.81, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Atara Biotherape's Piotroski F-Score?
Atara Biotherape (ATRA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Atara Biotherape's earnings high quality?
Atara Biotherape (ATRA) has an earnings quality ratio of -1.56x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Atara Biotherape cover its interest payments?
Atara Biotherape (ATRA) has an interest coverage ratio of 9.5x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Atara Biotherape?
Atara Biotherape (ATRA) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.